A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease
By F. Grodstein, J. Manson, Graham A Colditz, Walter C. Willett, F. Speizer, MR Stampfer. Annals of Internal Medicine, 2000
1,080 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics
View Paper: https://www.semanticscholar.org/paper/ff8a5177853f3b8fc1caff4cf368373411d36658
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
Citations in the corpus
- National use of postmenopausal hormone therapy: annual trends and response to recent evidence. (2004, result): “These findings from randomized trials contrast with prior observational studies that suggested cardiovascular benefits.(4-6) Based on the quality of recent data, new guidelines recommend against routine hormone therapy use for chronic conditions,(7) and current users have been advised to taper doses”
- A review of uses of health care utilization databases for epidemiologic research on therapeutics. (2005, background): “For example, randomized trials showed an initial harmful cardiovascular effect of hormone replacement therapy (HRT) [112,113], whereas observational studies failed to uncover these initial risks [114].”
- Evaluating medication effects outside of clinical trials: new-user designs. (2003, background): “Several of the large prospective cohort studies of HRT (7, 8) included many women who had been using estrogens for some time prior to entry into the study and the beginning of follow-up.”
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. (2002, background): “At least 1 observational study has suggested that that use of estrogen plus progestin is associated with higher risk of stroke than estrogen alone.(14) In WHI, there was no indication that excess strokes due to estrogen plus progestin were more likely to occur in older women, in women with prior str”
- The 2012 Hormone Therapy Position Statement of The North American Menopause Society (2012, positive): “duration of HT use is associated with a reduced risk of CHD and related mortality.(166) The WHI RCTs and observational study suggest a pattern of lower risk of CHD among women who used HT for 5 or more years,(40) but this is not conclusive and should be considered in light of other factors altered b”
- Cardiovascular Risks Associated with Gender and Aging (2019, background): “Experimental studies in mice have also reported the cardioprotective eff ct in both males and f m les, via mechanism whic include those whic support mitochondrial homeosta is and reduced oxidative stress [8,132,133].”
- Best Care at Lower Cost: The Path to Continuously Learning Health Care in America (2013, background): “Initial observational studies of women taking hormone replacement therapy suggested a reduction in the risk of heart disease in the range of 30 to 50 percent (Grady et al., 1992; Grodstein et al., 2000).”